Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMY)
Filing Type: Form 8-K (Current Report)
Date of Report: April 29, 2021
Reporting Period: First Quarter of 2021
This filing serves as a notification that the Company issued an Earnings Press Release and supplemental information regarding its financial results for the first quarter of 2021. The filing incorporates by reference the press release (Exhibit 99.1), supplemental information (Exhibit 99.2), and presentation materials (Exhibit 99.3).
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced Earnings Press Release and Supplemental Information, which are incorporated by reference but not detailed in the body of this 8-K form.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. It directs investors to the Earnings Press Release and Supplemental Information for a comparison of financial results.
Guidance, Outlook, and Risks
- Management Commentary: The Company posted a presentation on its website regarding financial and operating initiatives available during the conference call held on April 29, 2021.
- Non-GAAP Measures: The presentation includes references to non-GAAP financial information. Reconciliations to GAAP measures are available in the Supplemental Information (Exhibit 99.2).
- Regulatory Note: Information in Item 7.01 (Regulation FD Disclosure) and the associated presentation is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities thereof, except as specifically incorporated by reference in future filings.
Investor Verification Checklist
- Review the Earnings Press Release (Exhibit 99.1) for specific Q1 2021 revenue and earnings figures.
- Examine the Supplemental Information (Exhibit 99.2) for reconciliations between non-GAAP and GAAP financial measures.
- Access the Bristol Myers Presentation (Exhibit 99.3) for details on financial and operating initiatives.
- Verify the Company's status as a non-emerging growth company as indicated in the filing.